Treatment Trials

1 Clinical Trials for Various Conditions

Focus your search

      RECRUITING
      A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
      Description

      This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4859 in adult participants with intrahepatic cholangiocarcinoma (iCCA) or other advanced solid tumors with FGFR2 and/or FGFR3 genetic alternations.

      Conditions
      Intrahepatic Cholangiocarcinoma (Icc)CholangiocarcinomaOther Solid Tumors, AdultFGFR2 Gene Fusion/RearrangementFGFR2 Gene AmplificationFGFR2 Gene Short VariantsFGFR3 Gene Fusion/RearrangementFGFR3 Gene AmplificationFGFR3 Gene Short VariantsFGFR2 Genetic AlterationsFGFR3 Genetic AlterationsAdvanced Solid Tumors
      Talk to us